-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BR-790 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BR-790 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BR-790 in Solid Tumor Drug Details: BR-790 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GL-0034 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GL-0034 in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GL-0034 in Type 2 Diabetes Drug Details: GL-0034 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Refractory Multiple Myeloma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Plasma Cell Neoplasm Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Relapsed Multiple Myeloma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Refractory Multiple Myeloma Drug Details:...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...